Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

"After selling our rights back to Takeda three years ago, we have built an exciting and differentiated pipeline, which we believe will generate multiple value-creating opportunities in the near-term. Our R&D and financial strategy is independent of soticlestat's outcome. We will advance our pipeline thoughtfully and continue to apply the fiscal discipline to achieve our goals," remarked Dr. Levin. Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizu ...